ArriVent BioPharma, Inc. - 10-Q Filing
ArriVent BioPharma reports Q3 2026 financial results and details ongoing collaborative arrangements with Shanghai Allist, Lepu Biopharma, and Alphamab.
Tickers: $AVBP
Read the full article at SEC EDGAR
Part of the story ArriVent BioPharma, Inc. - 10-Q Filing (3 articles)